STENOVA - A Study to Evaluate Safety, Tolerability, PK and PD of AGMB-129 in Patients With Fibrostenotic Crohn's Disease

NCT05843578 · clinicaltrials.gov ↗

PHASE2

Phase

ACTIVE_NOT_RECRUITING

Status

103

Enrollment

INDUSTRY

Sponsor class

Conditions

Fibrostenotic Crohn's Disease

Interventions

DRUG: AGMB-129
DRUG: Placebo

Sponsor

Agomab Spain S.L.U.